PatentsThe AIMTM technology is the subject of an intellectual property portfolio that was developed by Johns Hopkins University over the past decade.
The portfolio consists of 7 issued US patents, several issued patents in other countries, and dozens of pending patents in the US and elsewhere.
These patents describe the construction and use of aAPC for a wide variety of applications.
A particularly strong aspect to the intellectual property is the breadth of aAPC and matrix types that are covered by the patent estate.
The patents include both composition of matter and use.
NexImmune holds an exclusive license to the entire portfolio for all uses in all territories.
Perica, K., Bieler, J.G., Schütz, C., Varela, J.C., Douglass, J., Skora,A., Chiu, Y.L., Oelke, M., Kinzler, K., Zhou, S., Vogelstein, B., Schneck, J.P. Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy. ACS Nano (2015) 10.1021/5b02829
Perica, K., Tu, A., Richter, A., Bieler, J.G, Edidin, M., Schneck, J.S. Magnetic-field-induced T cell receptor clustering by nanoparticles enhances T cell activation and stimulates antitumor activity in vivo. ACS Nano (2014) 10.1021/nn405520d
Sunshine, JC, Perica, K, Schneck, JP, Green, JJ. Particle shape dependence of CD8þ T cell activation by artificial antigen presenting cells. Biomaterials, 35 (2014) 269e277.
Perica, K, De León Mederob, A, Duraib, M, Chiub, YL, Glick Bielerb, J, Sibenerb, L, Niemöllerc, M, Assenmacherc, M, Richterc, A, Edidind, M, Oelkeb, M, Schneck, J. Nanoscale artificial antigen presenting Cells for T cell immunotherapy. Nanomedicine, 10(1)(2014):119-129.
Shena, C, Chenga, K, Miaoa, S, Wanga, W, Heb, Y, Mengb, F, Zhangb, J. Latex bead-based artificial antigen-presenting cells induce tumor-specific CTL responses in the native T-cell repertoires and inhibit tumor growth. Immunology Letters, 150 (2013) 1–11.
Chiu Y, Schneck JP, Oelke M. HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL Journal Visual Experiments, 50 (2011).
Jessica B. Lee, Mathias Oelke, Lakshmi Ramachandra, David H. Canaday, Jonathan P. Schneck. Decline of influenza-specific CD8+ T cell repertoire in healthy geriatric donors. Immuno Ageing, 2011 Aug 16;8:6
Ndhlovu ZM, Oelke M, Schneck JP, Griffin DE. Dynamic regulation of functionally distinct virus-specific T cells. Proceedings of the National Academy of Science, 107(8):3669-74, 2010.
Yue C, Oelke M, Schneck J, Paulaitis ME. Novel cellular microarray assay for profiling T-cell peptide antigen specificities. Journal of Proteome Research, 9(11):5629-37, 2010.
Giuntoli II RL, Webb TJ, Zoso A, Rogers O, Diaz-Montes TP, Bristow RE, Oelke M. Ovarian cancer-associated ascites demonstrates altered immune environment: Implications for antitumor immunity. Anticancer Research, 29(8):2875-84, 2009.
Tonya J. Webb, Joan G. Bieler, Jonathan P. Schneck, and Mathias Oelke. Ex vivo induction and expansion of Natural Killer T cells by CD1d1-Ig coated artificial antigen presenting cells. Journal of Immunological Methods, 31;346(1-2):38-44, 2009.
Ndhlovu ZM, Angenendt M, Heckel D, Schneck JP, Griffin DE, Oelke M. Development of an artificial antigen-presenting cell (aAPC)-based assay for the detection of low frequency virus-specific CD8+ T cells in whole blood with application to measles virus Clinical Vaccine Immunology, 16(7):1066-73, 2009.
Ugel S, Zoso A, De Santo C, Li Y, Marigo I, Zanovello P, Scarselli E, Cipriani B, Oelke M, Schneck JP, Bronte V. In vivo administration of artificial Antigen Presenting Cells activates low-avidity T cells for treatment of cancer. Cancer Research, 15(69): 9376-84, 2009.
Schutz C, Fleck M, Mackensen A, Zoso A, Halbritter D, Schneck JP, Oelke M. Killer-artificial-antigen presenting-cells (KaAPC): A novel strategy to delete specific T cells. Blood, 111(7):3546-52, 2008.
Durai M, Krueger C, Ye Z, Cheng L, Mackensen A, Oelke M, Schneck JP In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC). Cancer Immunology and Immunotherapy, 58(2):209-20,2008.
Webb TJ, Giuntoli II RL, Rogers O, Schneck JP, Oelke M. Ascites specific inhibition of CD1d-mediated activation of NKT cells. Clinical Cancer Research, 14(23):7652-8, 2008.
Paine A, Oelke M, Blasczyk R, Eiz-Vesper B. Expansion of human cytomegalovirus-specific T lymphocytes from unfractionated peripheral blood mononuclear cells using artificial antigen presenting cells. Transfusion, 47:2143-215, 2007.
Karabekin Z, Lytton SD, Silver PB, Sergeev YV, Schneck JP, Caspi RR. Antigen/MHC Class II/Ig dimers for study of uveitogenic T Cells IRBP p161-180 presented by both IA & IE molecules. Investigative Opthamology & Visual Science, Vol. 46 (10): 3769-3776, 2005.
Oelke M and Schneck JP. HLA-Ig based artificial antigen-presenting cells: Setting the terms of engagement. Journal of Clinical Immunology, 110(3):243-51, 2004.
Oelke M, Maus MV, Didiano D, June C, Mackensen A, Schneck JP. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig coated artificial Antigen Presenting Cells. Nature Medicine, 9(5):619-24, 2003.
Schütz C, Oelke M, Schneck JP, Mackensen A, Fleck M. Killer-artificial-Antigen Presenting-Cells (KaAPC): The synthetic embodiment of a “guided missile” Future Medicine – Immunotherapy, 2(4):539-50, 2010.
Oelke M, Schneck JP. Overview of a HLA-Ig based "Lego-like system" for T cell monitoring, modulation and expansion. Immunol Res. 2010 Jul; 47(1-3):248-56.
Mathias Oelke, Christine Krueger and Jonathan P. Schneck Technological Advances in Adoptive Immunotherapy, Drugs of Today, 41:13-21, Jan. 2005.
Mathias Oelke, Christine Krueger, Robert L.Giuntoli II and Jonathan P. Schneck Artificial antigen-presenting cells (aAPCs): artificial solutions for real diseases. Trends in Molecular Medicine 2005 Sep;11(9):412-20.
Mathias Oelke, and Jonathan P. Schneck. Immunotherapy With Enhanced Self Immune Cells, Discovery Medicine, 4 (22): 203-7, June-August 2004.
Krueger C, Schneck JP, Oelke M. Quality and quantity: New strategies to improve immunotherapy of cancer. Trends in Molecular Medicine, 10(5):205-8, 2004.